Biomarkers for the prediction of major adverse cardiovascular events in patients with acute coronary syndrome.

The aim of this study is to find novel biomarkers for prognosis in patients with acute coronary syndrome (ACS). We enrolled 245 eligible patients with ACS and compared the protein expression between the two groups, with or without major adverse cardiovascular events (MACE). To determine biomarkers for prognosis, we performed mass spectrometry analysis. We found 10 proteins in the serum that can be used to classify ACS with or without MACE and specific protein peaks at m/z 1921.0, 2124.2, and 20887.3 that were increased in patients with MACE. These peaks reliably predict MACE occurrence in patients with ACS, in addition to the widely accepted markers troponin and brain natriuretic peptide precursor. The characteristic changes in the peaks at m/z 1921.09, 2124.2, and 20887.3 correlate with poor prognosis in ACS patients. These proteins could potentially be used as predictive biomarkers to evaluate patient prognosis.